This site is intended for healthcare professionals
News

Phase III data show port delivery system with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration.- Genentech/Roche

Read time: 1 mins
Last updated:16th Mar 2021
Published:23rd Jul 2020
Condition: Age Related Macular Degeneration
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest